- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07947550
Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section
Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section: A Prospective Randomized Study
compare Perfusion Index with Internal Jugular Vein Collapsibility Index (IJVCI) as a predictor for post-spinal hypotension in parturient undergoing elective caesarean section.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Pre-anesthetic evaluation (History-Investigation - Examination) the day before surgery.
- NPO: 8 hours for solids, 2 hours for clear fluids.
- Pre-medication: Ranitidine 50 mg IV + Metoclopramide 10 mg IV, 30 minutes before anesthesia.
- 18-G IV cannula in the non-dominant forearm.
- Standard monitoring in the operating room: pulse oximetry (SpO2), NIBP, and ECG.
- Baseline measurements (HR, SBP, DBP, MAP, SpO2, PI, CI, IJVCI) recorded in the supine position with 15 degree left lateral tilt.
- All indicators will be measured in a single group before spinal anesthesia and comparisons will be made for the most sensitive maneuver in prediction of post spinal hypotension.
- Cardiac Index (CI) will be measured using cardiometry before spinal anesthesia.
- Perfusion Index (PI) is measured (Three consecutive readings are recorded at 1-minute intervals, will be repeated with another reading after delivery of baby).• The cut-off applied is: -
- 3.5 or less (low risk for hypotension)
- Greater than 3.5 (high risk for hypotension)
- Internal Jugular Vein Collapsibility Index will be measured by Ultrasonographic assessment and is performed by using a 6-10 MHz linear ultrasound probe. (The patient is placed supine with 15 degree left lateral tilt, The probe is positioned horizontally at the right side of the neck at the level of the middle thyroid cartilage, obtaining a transverse view of the right IJV. M-mode imaging during both spontaneous and deep breathing).
- Anteroposterior diameters of the IJV were estimated during the respiratory cycle. The IJV collapsibility index (IJVCI) was estimated via the following equation: Maximum diameter - lowest diameter/maximum diameter) 100% .
- The mean of three consecutive measurements is recorded for each breathing mode in quite respiratory cycle.
- Images will be saved for offline analysis.
- The cut-off applied is:
IJVCI < 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after spinal anesthesia in CS.
- Spinal anesthesia with intrathecal drug regimen 10-12 mg of 0.5% hyperbaric bupivacaine plus 25 micrograms (mic) Fentanyl].
- Co-loading with Ringer's lactate at 10ml/Kg will be administrated, along with spinal anesthesia placement .Data Collection
Baseline:
- Patient demographic data (age, ASA physical status, comorbidities, current medications, and BMI).
- Hemodynamics (Heart rate- Mean Arterial Blood Pressure - Systolic Blood Pressure -Oxygen Saturation) baseline reading before induction of spinal anesthesia.
- Preoperative IJVCI measurement by ultrasound imaging in supine position.
- Preoperative Perfusion Index reading.
- Preoperative Cardiac index reading.
Intraoperative:
-
Hemodynamic parameters (SBP, DBP, MAP, HR, SpO2) are recorded: -
- Every 1 minute for the first 10 minutes,
- Every 3 minutes until delivery,
- Every 5 minutes thereafter until end of surgery.
-
Total phenylephrine dose in microgram & Total Ephedrine dose (mg) [if persistent hypotension].
-
Total IV fluid volume (mL)
-
Total Blood loss (mL)
-
Total Urine output (mL)
-
Time from spinal block to delivery (min)
-
Total time of surgery.
-
All adverse events (nausea, vomiting, hypotension, bradycardia, oxygen desaturation) are recorded throughout.
Definition of Outcomes All outcome definitions are pre-specified and uniformly applied across all patients: -
- Post-spinal hypotension: A fall in systolic blood pressure (SBP) below 90 mmHg.
- Episodes are recorded from the time of spinal injection until delivery of the baby.
- Bradycardia: Heart rate below 50 beats per minute requiring pharmacological treatment with atropine 0.01 mg/kg IV.
Treatment of PSH
- First-line: 200 mL Ringer's lactate rapid IV infusion.
- If SBP remains below 90 mmHg phenylephrine 25-100 microgram if persistent hypotension gives Ephedrine 5-15 mg IV bolus.
- Bradycardia (HR < 50 bpm): Atropine 0.01 mg/kg IV.
- All vasopressor doses and additional fluid volumes administered are recorded.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nevine Soliman, MD
- Phone Number: 201128861471
- Email: mostafanevine@gmail.com
Study Locations
-
-
-
Alexandria, Egypt
- Recruiting
- Menoufia University,Faculty of Medicine
-
Contact:
- Nevine Soliman, MD
- Phone Number: 201128861471
- Email: mostafanevine@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adults undergoing Elective Cesarean Section at Menoufia University Hospitals
Description
Inclusion Criteria:
-
Full-term pregnant women undergoing elective cesarean section under spinal anesthesia (gestational age >= 37 weeks), singleton pregnancy.
- Age: 18-40 years.
- ASA I, II.
- BMI: 18.5-35 kg/m2.
Exclusion Criteria:
-
• Patient refusal or inability to provide informed consent.
- Emergency cesarean section.
- Known contraindications to spinal anesthesia (coagulopathy, local infection, elevated ICP).
- Baseline hypotension (SBP < 100 mmHg) prior to spinal anesthesia.
- Hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia).
- Placenta previa or antepartum hemorrhage.
- Multiple pregnancy or known fetal abnormality.
- BMI > 35 kg/m2.
- Pre-existing cardiovascular, cerebrovascular, or significant pulmonary disease.
- Gestational diabetes or uncontrolled systemic disease.
- Hemoglobin < 8 g/dL or known haemoglobinopathy.
- Peripheral vascular disease affects pulse oximetry signal quality.
- More than two attempts at lumbar puncture or failed.
- Inadequate spinal block.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Perfusion Index (PI) group measured by pulse oximeter
|
is measured using a validated multi-parameter monitor with a pulse oximetry module (Mindray uMEC 12 or equivalent).
|
|
Internal Jugular Vein Collapsibility Index group will be measured by ultrasonography
IJVCI < 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
compare the diagnostic accuracy assessed by ROC curve analysis between Perfusion Index (PI) & Internal Jugular Vein Collapsibility Index (IJVCI) combined with Cardiac Index (CI) in predicting post-spinal hypotension in elective CS patients.
Time Frame: • Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.
|
• Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
measure systolic arterial blood pressure changes after spinal anesthesia.
Time Frame: immediately after spinal anesthesia
|
immediately after spinal anesthesia
|
|
Total ephedrine dose or phenylephrine dose /milligram.
Time Frame: throughout the operation
|
throughout the operation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 9/2026 ANET 53
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.